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Background: The most common pediatric renal neoplasm is Wilms tumor, but clear cell sarcoma of the kidney
or synovial sarcoma of the kidney are also sometimes encountered. Accurate pathological diagnosis is important,
because adjuvant therapies including chemotherapy and radiotherapy differ according to the pathological type.
Case presentation: A 9-year-old boy presented with a headache, and ultrasonography, computed tomography,
and magnetic resonance imaging revealed a heterogeneous enhancement of soft tissue originating from the upper
pole of the left kidney, measuring approximately 11.0 × 10.0 × 8.0 cm. A left radical nephrectomy was performed
using an intraperitoneal approach through an anterior subcostal incision. Pathological examination suggested
clear cell sarcoma of the kidney or synovial sarcoma of the kidney based on morphological and immunohistological
features. Using genetic analysis, a final diagnosis of spindle cell pattern clear cell sarcoma of the kidney was made
based on the absence of the SYT-SSX fusion gene. After adjuvant chemo-radiotherapy was administered, no recurrence
or metastasis has been identified as of 60 months postoperatively.
Conclusion: In this case, it was difficult to discriminate clear cell sarcoma of the kidney from synovial sarcoma of the
kidney based on histopathological examination alone, and genetic analysis was required. Accurate pathological diagnosis
of pediatric renal tumor is important for determining optimal treatment and preventing recurrence and metastasis.
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Clear cell sarcoma of the kidney (CCSK) is a rare malignant
renal tumor that primarily occurs in children and was first
described by Kidd et al. in 1970 [1]. CCSK has recently
been regarded as a malignancy distinct from Wilms tumor,
and it has been classified as a tumor with unfavorable
histology, along with synovial sarcoma of the kidney (SSK)
[2]. SSK is also a rare malignant renal tumor, and was first
described by Argani et al. in 2000 [2]. CCSK and SSK are
difficult to differentiate pathologically from Wilms tumors,
sarcomatoid renal cell carcinoma, and undifferentiated
carcinoma. However, a precise diagnosis is important, as
these unique tumors require different treatment regimens.* Correspondence: kmizuno@med.nagoya-cu.ac.jp
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diagnosed with CCSK that was difficult to discriminate
from SSK.Case presentation
A 9-year-old boy presented with a headache; he was
treated for a common cold, but his symptoms did not
improve. Further examinations identified that he had high
blood pressure. Ultrasonography (Figure 1A), computed
tomography (Figure 1B), and magnetic resonance imaging
(Figure 1C) revealed heterogeneous enhancement of soft
tissue originating from the upper pole of the left kidney,
measuring approximately 11.0 × 10.0 × 8.0 cm. Further
evaluation including bone scan did not demonstrate any
evidence of metastasis. A left radical nephrectomy was
performed using an intraperitoneal approach through an
anterior subcostal incision. The tumor was solid, althoughThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Images of the left kidney tumor. (A) Ultrasonography showing a solid tumor in the left kidney. The tumor borders were clear, and
the tumor measured 11 × 10 × 8 cm. We detected mixed echogenicity inside the tumor. (B) Contrast-enhanced computed tomography showing
a solid tumor with clear borders and contrasted disproportionate, with no lymph node swelling or tumor embolism. (C) Magnetic resonance
imaging (T2-weighted) showing necrosis and hemorrhage inside the tumor. The tumor was suspected to have originated from left kidney
tissue (arrow; normal kidney).
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side the tumor (Figure 2A).
Pathological examination revealed a high nucleus to
cytoplasm ratio, proliferation of short, spindle-shaped
tumor cells (Figure 2B), and the presence of clear cells
with scant cytoplasm (Figure 2C). Staining for cytokeratin
yielded negative results, while tumor cells were positive for
vimentin, Bcl-2, CD-56, and CD-99 (Figure 3A). Differen-
tial diagnosis suggested CCSK or SSK; however, a final
diagnosis of spindle cell pattern CCSK was made based on
the absence of the SYT-SSX fusion gene by polymerase
chain reaction (Figure 3B) and the negative results for
transducin-like enhancer of split 1 (TLE1) and epithelial
membrane antigen (EMA) staining (Figure 3A). The final
pathological stage was T3aN0M0 stage 1, according to the
updated National Wilms Tumor Study-5 definition [3].
Concomitant chemo-radiotherapy was administered.
The patient underwent adjuvant radiotherapy to the left
nephrectomy bed (1080 cGy). As adjuvant chemotherapy,
vincristine, adriamycin, etoposide, and cyclophosphamide
were administered 1 day every 4 weeks over a 6-month
period, in accordance with the Japan Wilms Tumor Study
protocol [4].
No serious therapy-related side effects were observed.
No evidence of local recurrence or metastasis has been
identified as of 60 months following the operation.Discussion
In this case, CCSK was difficult to discriminate from SSK.
Differentiating CCSK from SSK, primitive neuroendocrine
tumor of the kidney, and sarcomatoid renal cell carcinoma
remains difficult [5-8]. No clinical or imaging characteristics
can aid a definitive preoperative diagnosis; thus, a diagnosis
of CCSK always requires pathological confirmation.
Pathologically, CCSK is characterized by tumor cells with
fine nuclear chromatin, pale cytoplasm, and indistinct cell
borders, these cells form nests separated by fibrovascular
stroma [5]. However, CCSK has multiple variant patterns,
including myxoid, sclerosing, cellular, epithelioid, palisading,
spindle-cell, storiform and anaplastic patterns [5]. SSK con-
sists of plump spindle cells in a mono- or biphasic pattern
with minimal cytoplasm and active mitotic figures [8]. In
addition, cystic lesions are commonly present and are lined
with epithelial cells that possess eosinophilic cytoplasm with
apical nuclei, resulting in a hobnail appearance [8].
Immunohistological staining can help to differentiate
CCSK from SSK, as CCSK typically stains positive for
vimentin and negative for cytokeratin, Bcl-2, CD-56, and
CD-99 [5,6]. However, Bcl-2, CD-56, and CD-99 may be
expressed in some cases. In the case of SSK, specimens
are typically positive for cytokeratin, vimentin, Bcl-2,
CD-56, CD-99, TLE1, and EMA, and are negative for actin,
desmin, S-100, and CD-34 [8-10].
Figure 3 Immunohistological staining for Bcl-2, CD-56, CD-99, TLE1, and EMA and polymerase chain reaction of SYT-SSX. (A) Positive
immunohistological staining for Bcl-2, CD-56, and CD-99 (reduced from × 400). Negative immunohistological staining for TLE1, and EMA
(reduced from × 400). (B) No SYT-SSX fusion gene was detected in tumor tissue by polymerase chain reaction.
Figure 2 Removed kidney and pathology of the tumor. (A) The tumor was solid, elastic soft, and light yellow in coloration, with degenerative
necrosis, hemorrhage and cystic lesion apparent inside the tumor. The resected kidney weighed 630 g. The borders of the normal kidney were
clear (arrow: normal kidney). (B) This part of the tumor exhibited clear cells with scant cytoplasm and circular. Nuclei, suggesting clear cell sarcoma of
the kidney (CCSK). Hematoxylin-eosin staining (reduced from× 400). (C) This part of the tumor showed spindle-shaped cells with a comparatively high
nucleus to cytoplasm ratio. These findings suggested SSK or spindle-pattern CCSK. Hematoxylin-eosin staining (reduced from× 400).
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morphological findings is often easy, though it can be
difficult when spindle-form cells are present. In
addition, immunohistochemical staining sometimes
shows atypical results. However, in genetic examinations,
polymerase chain reaction testing has greatly aided the
diagnosis of SSK by allowing detection of the SYT-SSX
fusion gene that results from translocation of the SYT
gene on chromosome 18 with the SSX gene on the X
chromosome [11,12]. No SYT-SSX fusion gene is present
in CCSK, though the chromosomal translocation t(10;17)
(q22;p13) is recognized in 12% of CCSK cases [13].
But, translocation t(10;17)(q22;p13) is not recognized
in this case.
In the present case, we observed a high nucleus to
cytoplasm ratio and an increased presence of spindle-
shaped tumor cells and clear cells with scant cytoplasm.
On immunohistochemical staining, tissues stained positive
for vimentin, Bcl-2, CD-56, and CD-99, but were negative
for cytokeratin, TLE1, and EMA. CCSK and SSK were
potential diagnoses based on the pathological examination,
but a final diagnosis of spindle -cell CCSK was made based
on the absence of the SYT-SSX fusion gene.
For CCSK treatment, surgery, radiotherapy, and chemo-
therapy are treatment options that may be administered
separately or in combination. Benchekroun et al. reported
the case of a patient who underwent surgery followed by
combination chemotherapy with cisplatin and doxorubi-
cin; no metastases developed over the course of 4 years,
whereas metastases occurred within months in two
patients who did not receive postoperative chemotherapy
or radiotherapy [14]. In addition, Bhayani et al. noted that
a patient treated with surgery and combination chemo-
therapy (actinomycin, vincristine and doxorubicin)
remained disease-free at 24 months postoperatively [15].
The National Wilms’ Tumor Study-5 trial showed a
4-year overall survival rate of 75% [16]. While surgical
resection and ifosfamide-based chemotherapy represent
the mainstays of SSK management, optimal treatment re-
mains unclear [8,17]. SSK exhibits an aggressive clinical
course with poor outcomes. Of the first 20 cases reported,
7 patients showed local or metastatic recurrence of the
disease and two patients have died [18].
In the future, pathological and genetic information is
likely to influence guidelines regarding treatment and
follow-up in patients with CCSK and SSK. Further studies
with a larger number of CCSK and SSK cases are needed
to provide more knowledge regarding the diagnosis of
pathological types and appropriate treatments.
Conclusion
We report herein the case of a 9-year-old boy who
underwent radical nephrectomy for a tumor in the left
kidney. A final diagnosis of CCSK was made based ongenetic analysis, and adjuvant chemo-radiotherapy was
administered. Accurate pathological diagnosis of pediatric
renal tumor is important for determining optimal treat-
ment and preventing recurrence and metastasis.
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